Glaukos Valuation Multiples

Glaukos Overview

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Founded

1998

HQ

Employees

1.1K

Website

glaukos.com

Sectors

Medical DevicesHealthcare SoftwareBioTechB2B SaaSVertical SaaSHealthTechLongevity

Financials (LTM)

Revenue: $534M

EBITDA: ($20M)

EV

$7B

Valuation Multiples

Multiples.vc

Start free trial

Glaukos Financials

Glaukos reported last 12-month revenue of $534M and negative EBITDA of ($20M).

In the same LTM period, Glaukos generated $436M in gross profit, ($20M) in EBITDA losses, and had net loss of ($47M).

Glaukos P&L

In the most recent fiscal year, Glaukos reported revenue of $507M and EBITDA of ($33M).

Glaukos expects next 12-month revenue of XXX and NTM EBITDA of XXX

Glaukos Stock Performance

Glaukos has current market cap of $7B, and enterprise value of $7B.

Glaukos' stock price is $121.12.

Glaukos Valuation Multiples

Glaukos trades at 12.9x EV/Revenue multiple, and (338.4x) EV/EBITDA.

Glaukos Financial Valuation Multiples

As of March 31, 2026, Glaukos has market cap of $7B and EV of $7B.

Equity research analysts estimate Glaukos' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Glaukos has a P/E ratio of (150.3x).

Glaukos Margins & Growth Rates

Glaukos' revenue in the last 12 month grew by 23%.

Glaukos' revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.

Glaukos' rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Glaukos' rule of X is 55% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Glaukos Public Comps

See public comps and valuation multiples for other Medical Devices and Healthcare Software comps.

Glaukos M&A Activity

Glaukos acquired XXX companies to date.

Last acquisition by Glaukos was on XXXXXXXX, XXXXX. Glaukos acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Glaukos Investment Activity

Glaukos invested in XXX companies to date.

Glaukos made its latest investment on XXXXXXXX, XXXXX. Glaukos invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).